Community perspective on child-friendly medications for drug-resistant TB: importance, priorities and advocacy
Int J Tuberc Lung Dis
.
2023 Sep 1;27(9):655-657.
doi: 10.5588/ijtld.23.0164.
Authors
L Viljoen
1
,
J Acaba
2
,
Y J P Agbassi
3
,
B Beko
4
,
C Goslett
5
,
G Hoddinott
1
,
B Kumar
6
,
R G Kumar
7
,
L McKenna
8
,
G Moses
3
,
T Sachs
1
,
S Seidel
9
,
A von Delft
10
Affiliations
1
Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.
2
The BENEFIT Kids Community Advisory Board (CAB), Asia Pacific Council of AIDS Service Organizations, Bangkok, Thailand.
3
Global Tuberculosis Community Advisory Board (TB CAB).
4
TB Proof, Cape Town, South Africa.
5
The BENEFIT Kids Community Advisory Board (CAB), Desmond Tutu TB Centre CAB, Cape Town, South Africa.
6
The BENEFIT Kids Community Advisory Board (CAB), Global Coalition of TB Advocates.
7
Touched by TB, National Coalition of People Affected by TB, India.
8
Treatment Action Group, New York, NY.
9
TB Alliance, New York, NY, USA.
10
The BENEFIT Kids Community Advisory Board (CAB), TB Proof, Cape Town, South Africa.
PMID:
37608482
PMCID:
PMC10443785
DOI:
10.5588/ijtld.23.0164
No abstract available
Publication types
Editorial
MeSH terms
Humans
Tuberculosis*
Tuberculosis, Multidrug-Resistant* / drug therapy